Zura Bio Stock Quote ZURA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.1697

Bid

3.12

Ask

3.93

Volume

391,789

3.145 Day's Range 3.72

2.00 52 Week Range 6.35

Market Cap

206.961M

Previous Close

3.60

Open

3.72

Last Trade

3.22

Last Trade Time

Financial Volume

$ 1,314,880

VWAP

3.3561

Average Volume (3m)

451,246

Shares Outstanding

65,293,530

Dividend Yield

PE Ratio

-2.99

Earnings Per Share (EPS)

-1.06

Revenue

Net Profit

-69.24M

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Show more

Sector

Lab Analytical Instruments

Industry

Blank Checks

Website

zurabio.com

Headquarters

Grand Cayman, Cym

Founded

2023

Zura Bio Ltd is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker ZURA. The last closing price for Zura Bio was $3.60. Over the last year, Zura Bio shares have traded in a share price range of $ 2.00 to $ 6.35.

Zura Bio currently has 65,293,530 shares outstanding. The market capitalization of Zura Bio is $235.06 million. Zura Bio has a price to earnings ratio (PE ratio) of -2.99.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.3803	-30.3362637363	4.55	4.85	3.1697	380326	4.21550464	CS
4	-1.7203	-35.1799591002	4.89	5.07	3.1697	336636	4.44856543	CS
12	-0.4203	-11.7075208914	3.59	5.07	3.1697	451246	4.24198461	CS
26	-2.0603	-39.3938814532	5.23	6.35	3.14	360155	4.09691082	CS
52	-1.1603	-26.7967667436	4.33	6.35	2	308131	3.86518352	CS
156	-4.8303	-60.37875	8	37.55	2	342800	6.56819806	CS
260	-4.8303	-60.37875	8	37.55	2	342800	6.56819806	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CEROCERo Therapeutics Holdings Inc	$ 0.2853 (52.40%)	1.17B
CYCNCyclerion Therapeutics Inc	$ 2.5306 (42.97%)	11.99M
SPPLSIMPPLE Ltd	$ 1.2503 (41.60%)	165.69M
PULMPulmatrix Inc	$ 6.5586 (39.54%)	5.37M
ZTEKZentek Ltd	$ 1.2574 (29.96%)	309.67k
TFFPTFF Pharmaceuticals Inc	$ 0.376101 (-76.49%)	9.35M
EYENEyenovia Inc	$ 0.10185 (-70.05%)	52.8M
CTXRCitius Pharmaceuticals Inc	$ 0.1974 (-39.89%)	11.26M
VVPRVivoPower International PLC	$ 0.8151 (-39.62%)	2.34M
IPWiPower Inc	$ 0.7302 (-39.15%)	1.15M
CEROCERo Therapeutics Holdings Inc	$ 0.2853 (52.40%)	1.15B
ELABElevai Labs Inc	$ 0.0211 (-19.47%)	377.69M
NVDANVIDIA Corporation	$ 141.98 (-3.26%)	244.07M
SPPLSIMPPLE Ltd	$ 1.2503 (41.60%)	164.49M
STISolidion Technology Inc	$ 0.44 (25.71%)	139.46M